Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Publi
December 12 2007 - 7:28PM
PR Newswire (US)
SAN MATEO, Calif., Dec. 12 /PRNewswire-FirstCall/ -- BioForm
Medical, Inc. (NASDAQ:BFRM) today announced the publication of a
multi-center, randomized, blinded comparative study of nasolabial
fold treatments reporting higher patient satisfaction with its
Radiesse(R) dermal filler than reported after treatment with either
Juvederm(TM) or Perlane(R). The results of this study were
published in the December 2007 Filler Issue of the Journal of
Dermatologic Surgery, a peer-reviewed publication of the American
Society of Dermatologic Surgery. In this first direct comparison
study of Radiesse dermal filler against two leading competitors,
the study concluded that 1) patients were substantially more
satisfied if they received Radiesse dermal filler than other
leading fillers tested, 2) patients who received Radiesse were
substantially more likely to return for future treatments, and 3)
Radiesse dermal filler offers advantages in durability and cost,
while exhibiting similar safety characteristics as hyaluronic acid
fillers. Results from two other studies were also published in this
special issue of Dermatologic Surgery. The results of the pivotal
U.S. clinical study of Radiesse dermal filler versus CosmoPlast(R)
(collagen), demonstrated superiority of Radiesse to CosmoPlast on
virtually every effectiveness measure in the study, and Radiesse
dermal filler was found to provide a comparable safety profile to
collagen. Three leading dermatologists, Dr. Neil Sadick, Dr. Bruce
Katz, and Dr. Deborshi Roy, also published in this special issue
their long-term clinical experience with Radiesse, also
demonstrating safety of Radiesse in clinical use and high patient
satisfaction. "We often hear from our customers that the reason
they choose Radiesse for many of their patients is first and
foremost that they believe their patients are more satisfied with
Radiesse than other dermal filler options. The published report of
the comparative study of Radiesse against leading hyaluronic acid
fillers demonstrates this difference in a well-controlled clinical
study setting," commented Steven Basta, Chief Executive Officer of
BioForm Medical. "We are grateful to the many investigators in the
U.S. and European clinical studies, and to the leading physicians
who routinely take time out of their practice to report on their
growing positive experiences with Radiesse." Radiesse vs. Juvederm
and Perlane Clinical Trial A 205-patient comparative study was
conducted at five clinical sites in Europe to assess patient
satisfaction and aesthetic improvement in treating nasolabial folds
with Radiesse dermal filler as compared to three leading hyaluronic
acid fillers, Perlane and two forms of Juvederm. The results of
this prospective, multi-center, randomized study, led by Marion
Moers-Carpi, MD, Hautok, Munich, Germany, demonstrated higher
patient satisfaction, higher likelihood to return for additional
treatment, and a greater likelihood to recommend treatment with
Radiesse dermal filler, as compared to the three hyaluronic acid
products tested: Juvederm 24 (not available in the U.S.), Juvederm
24HV (known as Juvederm Ultra in the U.S.) and Perlane. The study
was designed to measure the results achieved by several products on
a comparative basis after the completion of two treatments, at
baseline and at four months in order to achieve optimal correction.
The paper published in the Journal of Dermatologic Surgery reports
on results achieved through a 12-month follow-up after the second
treatment. The results from the study demonstrated that at 12
months after the last injection, 90% of Radiesse treated patients
rated their satisfaction as "satisfied" or "extremely satisfied"
compared to 48% with Perlane (p
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Jul 2023 to Jul 2024